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Body mass index is associated with altered renal
hemodynamics in non-obese healthy subjects
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Body mass index is associated with altered renal hemodynamics
in non-obese healthy subjects.
Background. Weight excess is associated with increased renal
risk. Data in overt obesity suggest a role for altered renal hemo-
dynamics. Whether body mass index (BMI) is also relevant to
renal function in non-obese subjects is unknown.
Methods. We studied the relation between BMI and renal
hemodynamics in 102 healthy, non-obese (BMI <30 kg/m2)
subjects [59 males, 43 females, mean age 39 (18–69) years] in
a post-hoc analysis of subjects evaluated as prospective kidney
donors or as healthy volunteers in renal hemodynamic studies.
Results. Mean (±SD) BMI was 24.0 ± 2.8 kg/m2, mean ar-
terial pressure (MAP) 93 ± 11 mm Hg, glomerular filtration
rate (GFR, iothalamate clearance) 111 ± 19 mL/min/1.73m2,
effective renal plasma flow (ERPF, hippuran clearance) 458 ±
108 mL/min/1.73m2, FF (GFR/ERPF) 0.25 ± 0.04. On uni-
variate analysis, BMI correlated negatively with ERPF/1.73m2
body surface area (BSA) (r = −0.46; P < 0.001), GFR/1.73m2
BSA (r = −0.24, P = 0.013) and positively with FF (r = 0.45,
P < 0.001), and age (r = 0.47, P < 0.001). On multivariate
analysis both BMI and age were independent predictors of
ERPF/1.73m2 BSA (negative) and FF (positive, all P < 0.05).
Age was the only predictor of GFR/1.73m2 BSA (negative).
Analyzed for renal function indexed for height (h), BMI cor-
related negatively with ERPF/h (r = −0.274, P = 0.005), but
not with GFR/h (r = 0.13, P = 0.899). On multivariate analysis
both BMI (positive) and age (negative) were independent pre-
dictors for GFR/h (both P < 0.001). Age was the only predictor
for ERPF/h (negative). Predictors for FF (BMI and age, both
positive) were by definition unaltered.
Conclusion. The impact of BMI on renal function is not lim-
ited to overt obesity, as in subjects with BMI <30 kg/m2 a higher
BMI is associated with higher FF, that is, a higher GFR relative
to ERPF. This suggests an altered afferent/efferent balance and
higher glomerular pressure (i.e., a potentially unfavorable renal
hemodynamic profile) that may confer enhanced renal suscep-
tibility when other factors, such as hypertension or diabetes are
superimposed.
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Obesity is increasingly recognized as a risk factor for
renal function loss in several conditions such as after
unilateral nephrectomy [1], IgA nephritis [2], and renal
transplant recipients [3–6], although not all studies are
equivocal. The mechanism underlying the increased re-
nal risk of obesity is only partly characterized. It may
be related to the concomitant cardiovascular and renal
risk factors associated with obesity, such as hypertension
and diabetes mellitus [7–12]. In line with this assumption,
altered renal hemodynamics have been implicated,
as hyperfiltration—attributed to impaired glucose
tolerance—is reported in obese subjects [7, 9, 13]. How-
ever, experimental and clinical studies suggested an
increased renal risk in obese subjects without overt co-
morbidity as well [1, 14–16].
Weight excess is a continuous trait, and on a popu-
lation basis, moderate weight excess has a much higher
prevalence than overt obesity [body mass index (BMI)
>30 kg/m2]. Data in renal transplant recipients suggest
that the impact of BMI on long-term renal risk is not lim-
ited to subjects with overt obesity [5], but the relation-
ship between BMI and renal hemodynamics in subjects
in the non-obese range has not been well characterized.
Therefore, in the present study we investigated the rela-
tionship between BMI and renal hemodynamics in non-
obese subjects, in a post-hoc analysis of data obtained in
healthy subjects evaluated as prospective kidney donors
or as healthy volunteers in renal hemodynamic studies.
METHODS
Patients
The study group consisted of 102 healthy non-obese
subjects [59 males, 43 females, mean age 39 (18–69) years]
in whom renal hemodynamic measurements had been
performed in our department. The subjects were either
healthy subjects [N = 61, male/female ratio 27/34, mean
age, 47 (21–69) years] screened for kidney donation or
healthy subjects [N = 41, male/female ratio 32/9, mean
age, 24 (18–46) years] previously studied in experimental
protocols including renal hemodynamic measurements
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as reported previously ([17, 18] and unpublished data).
The healthy volunteers were studied during a standard-
ized liberal (200 mmol Na+/day) sodium intake and
prospective kidney donors on an unrestricted sodium in-
take. Exclusion criteria for the present analysis were: hy-
pertension (defined as repeated seated blood pressure
>140/90 mm Hg), diabetes mellitus (defined as fasting
blood glucose >6.7 mmol/L and/or 2-hour postglucose
concentration >11.1 mmol/L), and obesity (defined as
BMI >30 kg/m2). Prospective kidney donors declared un-
fit, for whatever reason, to donate a kidney were excluded
as well.
Renal hemodynamic measurements
Glomerular filtration rate (GFR) and effective renal
plasma flow (ERPF) were measured by constant infu-
sion of radiolabeled tracers, 125I-iothalamate, and 131I-
hippurate, respectively, the subjects being in a quiet
room, in the semi-supine position. After drawing a blank
blood sample, a priming solution containing 0.04 mL/kg
body weight of the infusion solution (0.04 MBq of 125I-
iothalamate and 0.03 MBq of 131I-hippurate) plus an extra
of 0.06 MBq of 125I-iothalamate was given at 0800 hours,
followed by infusion at 12 mL/h. In order to attain
stable plasma concentrations of both tracers, a 2-hour
stabilization period followed, after which baseline mea-
surements started at 1000 hours. The clearances were
calculated as (U×V)/P and (I×V)/P, respectively. U×V
represents the urinary excretion of the tracer, I×V repre-
sents the infusion rate of the tracer, and P represents the
tracer value in plasma at the end of each clearance period.
This method corrects for incomplete bladder emptying
and dead space, by multiplying the urinary clearance of
125I-iothalamate with the ratio of the plasma and urinary
clearance of 131I-hippurate [19, 20]. The filtration frac-
tion (FF) was calculated as the ratio of GFR and ERPF
and expressed as percentage. Renal vascular resistance
(RVR) was calculated as mean arterial pressure (MAP)
divided by ERPF. Blood pressure was measured noninva-
sively during the renal function measurements by sphyg-
momanometer. MAP was calculated as diastolic pressure
plus one third of pulse pressure. Fat-free mass was esti-
mated as described by Garrow [21] and Salazar [22] as:
[weight × (1-A)] + [B × height2], with A being 0.715 and
0.713, and B being 12.1 and 9.74 for males and females,
respectively. Fat mass was calculated as total body weight
minus fat-free mass.
Data analysis
To comply with common practice in the literature,
data on renal hemodynamic parameters were indexed
per 1.73m2 body surface area (BSA). However, BSA as
such is correlated with BMI. As this could induce bias
when analyzing for the relationship between renal param-
Table 1. Population characteristics (N = 102)
Male/female 59/43
Age years 39 ± 14
Weight kg 75 ± 11
Fat-free mass kg 57 ± 9
Fat mass kg 19 ± 6
Length m 1.77 ± 0.10
BMI kg/m2 24.0 ± 2.8
MAP mm Hg 93 ± 11
GFR/BSA mL/min/1.73 m2 111 ± 19
ERPF/BSA mL/min/1.73 m2 458 ± 108
FF 0.25 ± 0.04
RVR/BSA mm Hg × 1.73/mL/min 0.22 ± 0.06
GFR/height mL/min/m 69 ± 12
ERPF/height mL/min/m 286 ± 67
RVR/height mm Hg × m/mL/min 0.35 ± 0.10
Abbreviations are: BMI, body mass index; MAP, mean arterial pressure;
GFR, glomerular filtration rate; BSA, body surface area; ERPF, effective renal
plasma flow; RVR, renal vascular resistance; FF, filtration fraction.
Data are mean ± SE.
eters/1.73m2 and BMI, we also indexed the renal hemo-
dynamic parameters for height [14, 23]. Data are given
for both separately.
Data are presented as mean ± standard deviation. As-
sociations were analyzed by univariate regression analy-
sis (Pearson). In addition, multilinear regression analysis
was applied with BMI, age, and MAP as independent
variables entered into the regression equation and re-
nal hemodynamic parameters (GFR, ERPF, FF, and
RVR, respectively) as dependent variables. Finally, to test
whether the relationship between BMI and renal hemo-
dynamic parameters was biased by gender differences, or
by selection bias due to differences in recruitment source
(i.e., healthy volunteer or prospective kidney donor), we
also analyzed our data by general linear modeling, includ-
ing gender and recruitment source as fixed factors in the
analysis.
Statistical computations were performed using SPSS,
version 10.0 software (SPSS, Inc., Chicago, IL, USA). A
P value < 0.05 was considered statistically significant.
RESULTS
Patient characteristics are presented in Table 1. All
subjects had normal renal function. Thirty-eight subjects
were overweight, defined as a BMI >25 kg/m2. BMI was
higher in older patients, as apparent from a positive cor-
relation between age and BMI (r = 0.47, P < 0.001).
Figure 1 shows the univariate correlations between
BMI and renal hemodynamics indexed for BSA (left pan-
els) and height (right panels), respectively. BMI corre-
lated negatively with the BSA-indexed values of ERPF
(r = −0.46, P < 0.001) and GFR (r = −0.24, P = 0.013)
and positively with FF (r = 0.45, P < 0.001) (Fig. 2) and
RVR (r = 0.54, P < 0.001) (data not shown). Univariate
analysis for height-indexed renal hemodynamics showed
that BMI correlated negatively with ERPF/h (r = −0.274,
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Fig. 1. Scatterplots showing the univariate
correlation between body mass index (BMI)
and effective renal plasma flow (ERPF) and
glomerular filtration rate (GFR) indexed for
body surface area (BSA) (left panels), as well














Fig. 2. Scatterplot showing the univariate correlation between body
mass index (BMI) and filtration fraction (FF).
P = 0.005), but not with GFR/h (r = 0.13, P = 0.89). The
correlation with FF was similar, by definition. In accor-
dance with the correlation between BMI and FF, fat mass
also correlated positively with FF (r = 0.45, P < 0.001)
(Fig. 3). Fat-free mass correlated positively with uncor-
rected GFR (r = 0.48, P < 0.001)—but not with BSA-
corrected or height-corrected GFR. No correlation was
present between fat-free mass and BMI (r = 0.01, NS).
Data on multivariate analysis are given in Table 2. As
to the BSA-indexed renal parameters, both BMI and age
independently predicted ERPF (negatively), FF (posi-
tively) and RVR (positively). Age was the only predictor
of GFR (negative). MAP was not a predictor of renal
hemodynamics. Multivariate data for the height-indexed
renal parameters are given in Table 3. In this analy-
sis, age was the only predictor for ERPF and RVR (for
both negative). Both BMI (positive) and age (negative)













Fig. 3. Scatterplot showing the univariate correlation between fat mass
and filtration fraction (FF).
Figure 4. Predictors for FF (BMI and age, both positive)
were by definition similar to those for the BSA-indexed
values. To test whether gender or recruitment source af-
fected the relationship between BMI and renal hemo-
dynamics, general linear modeling was performed with
gender, and recruitment source included as factors in the
analysis. Whereas this confirmed the significant impact of
BMI (r2 of the model predicting FF: 0.370, P < 0.001) no
significant effect of gender or recruitment source could
be detected.
DISCUSSION
In this study we found that a higher BMI is associ-
ated with a higher FF in healthy non-obese subjects,
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Table 2. Multivariate data on determinants of renal hemodynamics, indexed for BSA
GFR (r2 = 0.27) ERPF (r2 = 0.51) FF (r2 = 0.30) RVR (r2 = 0.70)
b P b P b P b P
BMI −0.012 0.905 −0.174 0.033 0.267 0.007 0.161 0.013
MAP 0.069 0.459 0.058 0.447 0.021 0.816 0.374 <0.001
Age −0.553 <0.001 −0.649 <0.001 0.382 <0.001 0.532 <0.001
See Table 1 for abbreviations. BMI, MAP, and age are entered in the model as independent variables; for GFR, ERPF, FF, and RVR as dependent variables. R-square
for the respective models for GFR, ERPF, FF, and RVR is given in the upper line. Beta-values (standard coefficient b) and P values are given for each independent
variable separately.
Table 3. Multivariate data on determinants of renal hemodynamics, indexed for height
GFR (r2 = 0.31) ERPF (r2 = 0.48) FF (r2 = 0.30) RVR (r2 = 0.68)
b P b P b P b P
BMI 0.292 0.003 0.049 0.558 0.267 0.007 −0.009 0.893
MAP 0.073 0.422 0.060 0.449 0.021 0.816 0.399 <0.001
Age −0.656 <0.001 −0.740 <0.001 0.382 <0.001 0.608 <0.001
See Table 1 for abbreviations. BMI, MAP, and age are entered in the model as independent variables; for GFR, ERPF, FF, and RVR as dependent variables. R-square




















Linear (bmi <median) R2 = 0.2064
Linear (bmi >median) R2 = 0.4502
Fig. 4. Multivariate relationship between glomerular filtration rate
(GFR) indexed for height, age, and body mass index (BMI). The im-
pact of BMI is visualized by presenting the data points according to
a breakup for BMI below or above the median BMI of this popula-
tion (median BMI, 23.8 kg/m2), demonstrating a steeper slope between
GFR/h and age for subjects with BMI above the median.
suggesting an effect of BMI on afferent/efferent vaso-
motor balance. Thus, the unfavorable effects of excess
weight on renal hemodynamics are not limited to overt
obesity.
To compare renal hemodynamics between different in-
dividuals with different body size, renal function data are
usually indexed for BSA. However, this approach is chal-
lenged by studies showing that renal function correlates
with height rather than BSA in obese subjects [14, 23].
For our purpose, moreover, it is relevant to realize that
weight gain in a subject of a given body size results in
a rise in BSA as well as BMI. Thus, BMI and BSA are
strongly correlated. Obviously, this will bias any analysis
of the relationship between BSA-indexed renal parame-
ters and BMI toward a negative association. Therefore,
we also performed our analysis on height-indexed renal
function data. When indexed for BSA, both GFR and
ERPF were negatively correlated to BMI, but for GFR
this association was annihilated by indexing for height.
Our finding, however, that FF is higher in subjects with
a higher BMI is not dependent on the way renal func-
tion is indexed and thus stands out as a robust finding not
affected by assumptions on the validity of indexing.
Aging has been shown to be associated with a decline
in renal function in healthy subjects [24] although co-
morbidity has been argued to be more important [25]. In
our study population a higher age was associated with a
higher BMI. Thus, the association between BMI and re-
nal hemodynamics observed here might be an age-related
artifact. Therefore, we performed multivariate analysis,
including age as well as BMI. This revealed that age was
indeed the best predictor of renal hemodynamics, irre-
spective of how renal function was indexed, with lower
GFR and ERPF, and higher FF in older patients. Never-
theless, BMI remained an independent positive predictor
for FF.
The independent predictive value of age and BMI for
GFR/height could suggest that the alleged age-related
decline in renal function will be more readily apparent in
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subjects with a higher BMI. However, our cross-sectional
data set does not allow support for such a conclusion,
and longitudinal data would be needed to that purpose.
Moreover, in our cross-sectional data set the steeper slope
between age and GFR/height in the subjects with higher
BMI was due to a higher GFR in younger subjects rather
than to a lower GFR in the older subjects.
So far, no other studies reported on the impact of BMI
on renal hemodynamics in subjects without overt obesity.
Most studies on BMI compare lean and (morbidly) obese
subjects with obesity defined according to varying cut-off
levels. Our observation of a linear relationship between
FF and BMI without an apparent cut-off or threshold
justifies our approach of analyzing BMI as a continuous
trait. The cut-off level of 30 kg/m2 that we used to exclude
overt obesity is in accordance with the National Health
and Nutrition Examination Survey [26].
Most studies report that GFR is elevated in obesity.
Ribstein et al [9] found that height-indexed GFR was ap-
proximately 10% higher in 20 obese normotensive sub-
jects (mean BMI of 33.2) than in lean subjects (mean BMI
of 22.4). Chagnac et al [27] reported elevated GFR (not
indexed) in severe obesity (BMI >38). An older study
on the relationship between body composition and re-
nal function in obesity reported a positive correlation
between creatinine clearance and fat-free body mass; as
fat-free body mass was elevated in obese subjects this ac-
counted for a higher creatinine clearance in morbid obe-
sity [22]. The higher GFR in obesity in those studies is in
line with the positive predictive value of BMI for GFR in
our multivariate analysis. Anastasio et al [14], however,
reported no difference in height-indexed GFR between
severely overweight (mean BMI of 46.8) normotensive
men and non-obese (BMI 25.6) control subjects.
Data on ERPF are somewhat more variable be-
tween studies. Anastasio et al [14] reported a normal
height-indexed ERPF in normotensive obese subjects
[14]. Other studies, however, found an elevated (height-
indexed) ERPF in normotensive as well as hyperten-
sive obese subjects [10]. Porter et al [15] found a higher
renal perfusion (per kidney volume) in mildly obese,
normotensive subjects during severe sodium restriction,
but not during liberal sodium intake. Scaglione et al
[8], by contrast, reported a lower (non-indexed) ERPF
in normotensive subjects with central obesity. Finally,
Schmieder et al [23] reported that height-indexed ERPF
was not affected by obesity in a mixed population of
hypertensive and normotensive subjects, whereas BSA-
indexed ERPF was lower in obese subjects. The absence
of impact of BMI on height-indexed ERPF, as well as the
negative predictive value of age for ERPF in the latter
study, is well in line with our multivariate data.
Differences in indexing may explain some of the above
discrepancies, but data on the relationship between FF
and BMI are not uniform either, indicating that the dis-
crepancies cannot fully be attributed to differences in in-
dexing. Some authors, in line with our data, report an ele-
vated FF in obesity [27]. Ribstein et al, however, found a
higher FF in obesity in hypertensive, but not in normoten-
sive, subjects [9], suggesting interaction between obesity
and hypertension. This is in line with data from Scaglione
et al [8], who found an elevated FF in (central) obesity
only in hypertensive, but not in normotensive subjects
with central or peripheral obesity. The discrepancies sug-
gest impact of comorbidity, such as hypertension [8, 9]
and insulin resistance [27], but differences in severity of
obesity, age, or sodium intake may also have affected the
impact of obesity on FF.
Several limitations of our study should be considered.
First, possible selection bias. We included only healthy
subjects, but our population was not homogeneous as to
recruitment source, with prospective kidney donors be-
ing older, and with over-representation of younger males
among the healthy volunteers. Moreover, being selected
for being healthy at middle age (i.e., donors) may se-
lect individuals that represent the healthiest part of their
age cohort, which is probably less so for healthy subjects
in their twenties. Thus, although we could not detect a
significant effect of recruitment source, bias by the het-
erogeneity in this population cannot be excluded, and it
would be relevant to test whether our findings also hold
in more homogenous populations. Second, our study was
not suitable to identify mechanisms underlying the rela-
tionship between BMI and renal hemodynamics—by its
post-hoc nature, and by lack of data on possibly relevant
factors such as body fat distribution [28], insulin sensitiv-
ity, or insulin levels, activity of the sympathetic nervous
system [13, 29, 30], the renin-angiotensin system (RAS)
[29, 31–33], lipids, and leptin levels. Data in the litera-
ture suggest involvement of these factors in renal hemo-
dynamic changes in obesity, and by inference they may
also be relevant to the relationship between BMI and
renal hemodynamics in non-obese subjects. Our study
did not include formal measurements of body composi-
tion. However, as the latter may be relevant as well [22],
we estimated fat mass and fat-free mass from anthropo-
morphic data, and found a significant positive correla-
tion between fat mass and FF. In accordance with data of
Salazar et al in a small number of normal and morbidly
obese subjects, GFR (uncorrected) correlated positively
with fat-free mass. However, in our non-obese popula-
tion, a higher BMI was not associated with a higher fat-
free mass—so the latter does not appear to account for
the impact of BMI on renal function that we observed.
A role for insulin resistance in obesity-associated
changes in renal function is suggested by the epidemi-
ologic association between waist-hip ratio and renal
function [28], as well as by the association between
obesity-associated increases in GFR (and FF) and the de-
gree of insulin resistance [34]. The latter association was
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blunted by liberal sodium intake [33], which is in line with
data from Porter et al, who found an obesity-associated
increase in renal perfusion during low sodium only. In
our study sodium intake was unrestricted in the major-
ity of the subjects (kidney donors), and standardized at
a liberal level in the others. Thus, in our study sodium
status, if anything, can be expected to have blunted the
relationship between BMI and renal hemodynamics. The
impact of sodium intake was suggested to imply a role
for the RAS [15], supported by the finding that the re-
nal hemodynamic response to RAS-blockade is propor-
tional to BMI in type II diabetes [35]. The mechanism
of the link between insulin resistance and renal hemody-
namic alterations in obesity has not been elucidated yet.
Hyperinsulinemia might be involved, but experimental
hyperinsulinemia does not lead to elevated FF, neither
in acute nor in chronic experiments [12, 36, 37], which
is at variance with this assumption. Recent data suggest
that leptin may be relevant. Serum leptin levels correlate
strongly with BMI [38], and leptin stimulates sympathetic
nervous activity and reactive oxygen species [39]. How-
ever, so far, in clinical studies, leptin levels could not be
identified as a renal risk factor [40, 41].
Animal data on the glomerular microcirculation in
obesity indicate changes resembling those after renal ab-
lation, with glomerular hypertension and hyperfiltration.
In obese Zucker rats, a genetic model of obesity, GFR was
either normal [42, 43] or elevated [44, 45], with either nor-
mal [45] or elevated glomerular capillary pressure [43].
In this model elevated GFR appears to precede glomeru-
losclerosis, without, however, being a prerequisite for re-
nal structural damage [42, 45]. An impaired myogenic
afferent vasoconstriction may be involved in the altered
glomerular hemodynamics [46]. Food restriction reduces
the elevated GFR [39], demonstrating the contribution
of a functional component alongside structural abnor-
malities. However, the mechanisms of the renal changes
in genetically obese models appear to be different from
those in man, for instance, regarding the role of the renin-
angiotensin system and the sympathetic nervous system
[29, 43]. Obesity induced by overfeeding in dogs and rab-
bits [47] may more closely mimic the human condition
[29]. In dogs, feeding-induced obesity leads to a con-
siderably elevated GFR and renal plasma flow already
after a few weeks, coinciding with structural changes
such as mesangial matrix expansion and cell proliferation
[7, 29], likely precursors of glomerulosclerosis. The ele-
vated GFR has been hypothesized to render the kidney
susceptible to progressive glomerulosclerosis, especially
when hyperlipidemia, hyperglycemia, or hypertension is
simultaneously present. Whether the mechanisms ob-
served in experimental obesity-associated renal damage
also apply to our observations on BMI and renal hemo-
dynamics in non-obese subjects, however, remains to be
investigated.
What is the clinical impact of our findings? It is well
established that the overall health risks of excess weight
are not limited to overt obesity [48]. As to renal risk,
data in renal transplant recipients showed that the re-
nal risk of excess weight is not limited to overt obesity
either [5]. In line with this, our data indicate that even
moderate overweight is associated with an unfavorable
renal hemodynamic pattern (i.e., an elevated FF). This
may render the kidney susceptible to damage by other
renal risk factors, such as hypertension, as supported by
the data of Ribstein et al [9]. As moderate overweight
has a much higher prevalence than overt obesity, the
population-attributable risk of overweight for renal dam-
age therefore deserves proper consideration.
CONCLUSION
The impact of BMI on renal hemodynamics is not lim-
ited to overt obesity, as also in subjects with BMI <30 kg/
m2 a higher BMI is associated with higher GFR relative to
ERPF, suggesting altered afferent/efferent balance and
a higher glomerular pressure. This potentially unfavor-
able renal hemodynamic profile may result in enhanced
renal susceptibility when other factors, such as hyperten-
sion, are superimposed. Prospective studies on the impact
of overweight on renal risk are needed to confirm these
findings.
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